Figure 4.
Micronuclei resulting from loss of KIF18A function in human cells infrequently lack lamin A/C. (A) Schematic of experimental design. Note that cells were either treated with siRNA (†) or nocodazole washout (††), but not both. (B) Plot showing percentage of micronucleated RPE1 cells following treatment with the indicated siRNAs or drug washout. n = 4,188 (RPE1 control KD), n = 3,536 (RPE1 control + p53 KD), n = 661 (KIF18A KO control KD), n = 869 (KIF18A KO control KD + p53 KD), n = 1,223 (RPE1 MAD2 KD), n = 1,157 (MAD2 KD + p53 KD), n = 4,005 (RPE1 + nocodazole washout), n = 2,189 (RPE1 1 Gy, control KD), n = 3,080 (RPE1 1 Gy, control KD + p53 KD). *, P < 0.0001 (Table S6). (C) Representative images of fixed, micronucleated RPE1 cells labeled with DAPI (DNA, blue) and lamin A/C (red). (D) Plot showing percentage of micronucleated cells that lacked complete lamin A/C within micronuclear envelopes following the indicated treatments. n = 485 (RPE1 control KD), n = 510 (RPE1 control + p53 KD), n = 807 (KIF18A KO control KD), n = 720 (KIF18A KO control KD + p53 KD), n = 631 (RPE1 MAD2 KD), n = 648 (RPE1 MAD2 KD + p53 KD), n = 726 (RPE1 + nocodazole washout), n = 622 (RPE1 1 Gy, control KD), n = 778 (RPE1 1 Gy, control KD + p53 KD). *, P < 0.01 (Table S7). (E) Plot showing percentage of micronuclei that lacked complete lamin A/C within micronuclear envelopes in RPE1 control and KIF18A KO cells subjected to DMSO treatment or nocodazole washout, as indicated. n = 161 (RPE1 untreated), n = 162 (RPE1 + DMSO washout), n = 171 (RPE1 + nocodazole washout), n = 253 (KIF18A KO untreated), n = 293 (KIF18A KO + DMSO washout), n = 278 (KIF18A KO + nocodazole washout). *, P < 0.01 (Table S8). Data are from three independent experiments (B, C, and E) and from four experiments (D). Indicated P values were calculated by χ2 analysis.

Micronuclei resulting from loss of KIF18A function in human cells infrequently lack lamin A/C. (A) Schematic of experimental design. Note that cells were either treated with siRNA (†) or nocodazole washout (††), but not both. (B) Plot showing percentage of micronucleated RPE1 cells following treatment with the indicated siRNAs or drug washout. n = 4,188 (RPE1 control KD), n = 3,536 (RPE1 control + p53 KD), n = 661 (KIF18A KO control KD), n = 869 (KIF18A KO control KD + p53 KD), n = 1,223 (RPE1 MAD2 KD), n = 1,157 (MAD2 KD + p53 KD), n = 4,005 (RPE1 + nocodazole washout), n = 2,189 (RPE1 1 Gy, control KD), n = 3,080 (RPE1 1 Gy, control KD + p53 KD). *, P < 0.0001 (Table S6). (C) Representative images of fixed, micronucleated RPE1 cells labeled with DAPI (DNA, blue) and lamin A/C (red). (D) Plot showing percentage of micronucleated cells that lacked complete lamin A/C within micronuclear envelopes following the indicated treatments. n = 485 (RPE1 control KD), n = 510 (RPE1 control + p53 KD), n = 807 (KIF18A KO control KD), n = 720 (KIF18A KO control KD + p53 KD), n = 631 (RPE1 MAD2 KD), n = 648 (RPE1 MAD2 KD + p53 KD), n = 726 (RPE1 + nocodazole washout), n = 622 (RPE1 1 Gy, control KD), n = 778 (RPE1 1 Gy, control KD + p53 KD). *, P < 0.01 (Table S7). (E) Plot showing percentage of micronuclei that lacked complete lamin A/C within micronuclear envelopes in RPE1 control and KIF18A KO cells subjected to DMSO treatment or nocodazole washout, as indicated. n = 161 (RPE1 untreated), n = 162 (RPE1 + DMSO washout), n = 171 (RPE1 + nocodazole washout), n = 253 (KIF18A KO untreated), n = 293 (KIF18A KO + DMSO washout), n = 278 (KIF18A KO + nocodazole washout). *, P < 0.01 (Table S8). Data are from three independent experiments (B, C, and E) and from four experiments (D). Indicated P values were calculated by χ2 analysis.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal